Study Name:
CA2209-9G7: Phase II multi-institutional proof of concept single-arm trial of Nivolumab in the treatment of patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors.

Phase:
Phase 2 Clinical Trial

EudraCT number:
2017-003336-37

National Investigator Coordinator:
Prof. Doctor José Luís Passos Coelho

Participating Countries:
Portugal

Sites in Portugal:
Hospital Beatriz Ângelo, IPO Lisboa, IPO Porto, IPO Coimbra

Sponsor:
Hospital Beatriz Ângelo

Status:
Recruitment